Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors

Targeted therapies as BRAF and MEK inhibitor combination have been approved as first-line treatment for BRAF-mutant melanoma. However, disease progression occurs in most of the patients within few months of therapy. Metabolic adaptations have been described in the context of acquired resistance to B...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Death Dis
Autors principals: Khamari, Raeeka, Trinh, Anne, Gabert, Pierre Elliott, Corazao-Rozas, Paola, Riveros-Cruz, Samuel, Balayssac, Stephane, Malet-Martino, Myriam, Dekiouk, Salim, Joncquel Chevalier Curt, Marie, Maboudou, Patrice, Garçon, Guillaume, Ravasi, Laura, Guerreschi, Pierre, Mortier, Laurent, Quesnel, Bruno, Marchetti, Philippe, Kluza, Jerome
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5832419/
https://ncbi.nlm.nih.gov/pubmed/29487283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-018-0340-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars